|
Otsuka America Pharmaceutical, Inc. (OAPI) was
established in the US in 1989 and has since built a
solid business foundation on strong Otsuka-developed
products. OAPI has commercialized a diversified
portfolio of products in United approved for use in the
following therapeutic categories::
• Schizophrenia
• Bipolar Disorder
• Adjunctive Therapy for Major Depressive Disorder
• Conditioning agent prior to allogeneic hematopoietic stem
cell transplantation in CML
• Clinically Significant Hypervolemic and Euvolemic Hyponatremia
• Intermittent Claudication
• Detection of H. Pylori
OAPI's products in the United
States include:
|
|
|
Click logos to visit
branded sites. |
OAPI |
Neuroscience |
 |
Learn More...
Please see
FULL PRESCRIBING INFORMATION
including
Boxed WARNINGS for ABILIFY. |
|
|
OAPI | Hospital Product |
|
|
Learn More...
Please see
FULL PRESCRIBING INFORMATION including
Boxed WARNING
for SAMSCA. |
|
|
OAPI | Oncology |
|
|
Learn More...
Please see
FULL PRESCRIBING INFORMATION
including
Boxed WARNING
for IV BUSULFEX. |
|
|
OAPI | Medical Device |
|
|
Learn
More... Please see
FULL PRESCRIBING INFORMATION for BreathTek. |
|
|
OAPI | Cardiovascular |
 |
Learn More...
Please see
FULL PRESCRIBING INFORMATION including
Boxed WARNING
for PLETAL.
|
